ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Samsung BioLogics Co., Ltd.

Business Summary

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2019 KRWUSD
Revenue701,591.85M601.61M
Gross Profit230,536.76M197.68M
Operating income92,084.47M78.96M
Income before tax82,495.19M70.73M
Net income202,904.09M173.98M
EBITDA224,627.48M192.61M
Diluted EPS3,066.632.62
Dividends Per Share00
Total Assets5,911.62B5,111.87M
Total liabilities1,557.17B1,346.51M
Total equity4,354.45B3,765.36M
Operating cash flow10,153.61M8.70M
Currency in KRWCurrency in USD

Historical Data

 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 91,278.02M 294,622.02M 464,629.33M 535,805.80M 701,591.85M
Gross Profit -39,120.09M 20,457.76M 122,304.94M 130,544.55M 230,536.76M
Operating income -203,844.82M -30,422.63M 65,979.40M 55,678.74M 92,084.47M
Income before tax -2,036.15B -101,678.33M -115,994.75M 302,975.83M 82,495.19M
Net income 1,920.17B -176,823.40M -96,972.11M 224,109.19M 202,904.09M
EBITDA -162,216.55M 29,727.25M 135,905.62M 147,129.29M 224,627.48M
Diluted EPS 29,021.06 -3,115 -1,466 3,387 3,066.63
Dividends Per Share -- 0 0 0 0
Total Assets 6,478.47B 7,533.01B 7,183.09B 5,980.40B 5,911.62B
Total liabilities 3,703.63B 3,450.63B 3,206.64B 1,824.94B 1,557.17B
Total equity 2,774.83B 4,082.37B 3,976.45B 4,155.46B 4,354.45B
Operating cash flow -265,513.75M -62,661.29M 149,816.32M 36,787.30M 10,153.61M
 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 80.64M 253.94M 410.99M 486.86M 601.61M
Gross Profit -34.56M 17.63M 108.18M 118.62M 197.68M
Operating income -180.10M -26.22M 58.36M 50.59M 78.96M
Income before tax -1,799.03M -87.63M -102.60M 275.30M 70.73M
Net income 1,696.56M -152.40M -85.77M 203.63M 173.98M
EBITDA -143.32M 25.62M 120.21M 133.69M 192.61M
Diluted EPS 25.64 -2.68 -1.29 3.07 2.62
Dividends Per Share -- 0 0 0 0
Total Assets 5,525.11M 6,236.97M 6,709.72M 5,359.74M 5,111.87M
Total liabilities 3,158.61M 2,856.96M 2,995.32M 1,635.54M 1,346.51M
Total equity 2,366.49M 3,380.01M 3,714.39M 3,724.20M 3,765.36M
Operating cash flow -234.59M -54.00M 132.52M 33.42M 8.70M

Valuation Measures

Dec 2019
PER141.19
ROA3.41%
ROE4.76%
Operating margin13.12%
Profit margin28.92%

Key executives

  • Chief Executive Officer & Director: Tae-Han Kim
  • Managing Director & Head-Operations Support: Ho-Yeol Yoon
  • Managing Director & Head-Information Technology: James J. Choi
  • Managing Director & Head-Process Technology: Yong-Ho An
  • Head-Compliance Support: Hyung-Woo Moon

Shareholders

  • Samsung C&T Corp. (43.4%)
  • Samsung Electronics Co., Ltd. (31.4%)
  • Invesco Advisers, Inc. (2.0%)
  • Samsung Asset Management Co., Ltd. (0.8%)
  • Canada Pension Plan Investment Board (0.6%)
  • The Vanguard Group, Inc. (0.5%)
  • BlackRock Fund Advisors (0.5%)
  • Norges Bank Investment Management (0.4%)
  • Fidelity Management & Research Co. LLC (0.2%)
  • Mirae Asset Global Investments Co., Ltd. (0.2%)

Contact Details

Related Companies

  • PengTai Greater China Co., Ltd.
  • Samsung BioLogics Co., Ltd. ESOA

Competitors

  • Lonza Group AG
  • Wuxi Biologics (Cayman) Inc.
  • Celltrion, Inc.
  • Binex Co., Ltd
  • AbClon, Inc.
  • BCWORLD PHARM. Co., Ltd.
  • Celltrion Healthcare Co., Ltd.
  • Coherus BioSciences, Inc.
  • EPIRUS Biopharmaceuticals, Inc.
  • Kodiak Sciences, Inc.
  • Momenta Pharmaceuticals, Inc.
  • PharmAbcine, Inc.
Last Updated on 25 May, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media